proinflammatory cytokine expression in patients with chronic obstructive pulmonary disease
Clicks: 166
ID: 201746
2010
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
166 views
27 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #70 of 121 articles by views in respirology (carlton, vic)
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 121 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The research goal was to investigate cytokine profile (IL-1p, 11_-1ра, IL-4, IL-6, IL-8, TNF-a and INF-у) in patients with chronic obstructive pulmonary disease (OOPD). The data of decreasing of anti-inflammatory IL-4 and increasing of proinflammatory cytokines in patients with OOPD were worked out. Inclusion of domestic immunomodulator of immunovenin in standard therapy of OOPD permitted to decrease concentration of proinflammatory cytokines and to increase the level of anti-inflammatory IL-4
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (70 words).
Try re-searching for a better abstract.
| Reference Key |
abdurakhmanova2010saratovskijproinflammatory
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;I.S. Abdurakhmanova;V.I. Nikulicheva;D.R. Vagapova;O.A. Enikeyev |
| Journal | respirology (carlton, vic) |
| Year | 2010 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.